
<!DOCTYPE html>
<!--[if lt IE 7]> <html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en"> <![endif]-->
<!--[if IE 7]>    <html class="no-js lt-ie9 lt-ie8" lang="en"> <![endif]-->
<!--[if IE 8]>    <html class="no-js lt-ie9" lang="en"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en"> <!--<![endif]-->
<head>
  <meta http-equiv="X-UA-Compatible" content="IE=edge" >
  <meta charset="utf-8">
  <!--<title>Utah State Legislature</title>-->
  <meta name="description" content="The official web site for the Utah State Legislature.">
  
  <!--<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0">-->
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=2.0, user-scalable=yes">
  <!--<meta name="viewport" content="width=1120">	-->
  <meta name="format-detection" content="telephone=no">
  <!--<link rel="icon" href="/images/mobile/apple-touch-icon.png" />
  <link rel="apple-touch-icon-precomposed" href="/images/mobile/apple-touch-icon.png"/>
  -->
  <link rel="icon" href="/images/mobile/dome.png" />
  <link rel="apple-touch-icon-precomposed" href="/images/mobile/dome.png"/>
  
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta names="apple-mobile-web-app-status-bar-style" content="black" />
  <link rel="stylesheet" href="/css/style.css">
  <!--[if IE]>
  	<link rel="stylesheet" href="/css/ie.css">
  <![endif]-->
  <script src="/js/libs/jquery-1.7.1.min.js"></script>
  <script src="/js/libs/modernizr-2.6.1.min.js"></script>
  <script src="/js/libs/jquery.browser_v2.3.min.js"></script>
  <script src="/js/libs/jquery.cookie.js"></script>
  <script src="/js/libs/css3-mediaqueries.js"></script>


<Title>Utah Legislature HB0309</Title>
<!-- File x:\xfer\hbillsht\int\HB0309.htm -->
<META Name = "keywords" Content="UTLE HB0309">

</head>
<body id="secondary" class="secondary">
	
	<div id="wrapper">
		
	<div id="header">
  		<h1 id="brand"><a href="/">Utah State Legislature</a></h1><!-- /#brand -->
		<form id="search" name="searchfrm" onsubmit="return doSearch(0);" method="post">			
	<!--
    <h2>Search</h2>
    
	<ul class="tab activator">
		<li><a id="activator-bill" class="active" >Bills</a></li>
		<li><a id="activator-code" >Code</a></li>
		<li><a id="activator-keyword" >Keyword</a></li>
	</ul>
	
	<p class="slot active" id="bill">
	<input type="text" name="number" id="bnumber" title="Enter Bill Number(HB 4)"  placeholder="Enter bill number, sponsor's last name, or subject here  "/><span id="sessionSelect">
		<select name="Sess" id="bsess" title="Select a Session">
        	<option value="all">All</option>
            <option selected="" value="2014GS">2014 General Session</option>
            <option value="2013S2">2013 2nd Special Session</option>
        	<option value="2013S1">2013 1st Special Session</option>
            <option value="2013H1">2013 House Session</option>
			<option value="2013GS">2013 General Session</option>
			<option value="2012S4">2012 4th Special Session
			</option><option value="2012GS">2012 General Session
			</option><option value="2011S3">2011 3rd Special Session
			</option><option value="2011S2">2011 2nd Special Session
			</option><option value="2011S1">2011 1st Special Session
			</option><option value="2011GS">2011 General Session
			</option><option value="2010S2">2010 2nd Special Session
			</option><option value="2010GS">2010 General Session
			</option><option value="2009S1">2009 1st Special Session
			</option><option value="2009GS">2009 General Session
			</option><option value="2008S2">2008 2nd Special Session
			</option><option value="2008GS">2008 General Session
			</option><option value="2007S1">2007 1st Special Session
			</option><option value="2007GS">2007 General Session
			</option><option value="2006S5">2006 5th Special Session
			</option><option value="2006S4">2006 4th Special Session
			</option><option value="2006S3">2006 3rd Special Session
			</option><option value="2006GS">2006 General Session
			</option><option value="2005S2">2005 2nd Special Session
			</option><option value="2005S1">2005 1st Special Session
			</option><option value="2005GS">2005 General Session
			</option><option value="2004S4">2004 4th Special Session
			</option><option value="2004S3">2004 3rd Special Session
			</option><option value="2004GS">2004 General Session
			</option><option value="2003S2">2003 2nd Special Session
			</option><option value="2003S1">2003 1st Special Session
			</option><option value="2003GS">2003 General Session
			</option><option value="2002S6">2002 6th Special Session
			</option><option value="2002S5">2002 5th Special Session
			</option><option value="2002S4">2002 4th Special Session
			</option><option value="2002S3">2002 3rd Special Session
			</option><option value="2002GS">2002 General Session
			</option><option value="2001S2">2001 2nd Special Session
			</option><option value="2001S1">2001 1st Special Session
			</option><option value="2001GS">2001 General Session
			</option><option value="2000GS">2000 General Session
			</option><option value="1999GS">1999 General Session
			</option><option value="1998GS">1998 General Session
			</option><option value="1997S2">1997 2nd Special Session
			</option><option value="1997S1">1997 1st Special Session
			</option><option value="1997GS">1997 General Session
			</option>  
		</select>
        </span>
	<input type="submit" value="Find" alt="Find" />
	</p>

	<p class="slot" id="code">
		<input type="text" id="gototext" name="gototext" title="Enter code section (36-12-1)" placeholder="Enter citation (Title-Chapter-Section) here" >
		<input type="submit" value="Find"  />
	</p>
	-->
	<p class="slot active" style="display:block;" id="keyword">
		<input type="text" maxlength="200" size="30" id="krequest" name="request" title="Enter Keyword(s)" placeholder="Enter keyword(s) here" >
		<input type="button" value="Bills" onclick="doSearch(1);" title="Search Bills Only"/>
        	<input type="button" value="Site" onclick="doSearch(2);" title="Search Entire Site"/>		
	</p>
    <!--<input type="hidden" name="searchbutton" value="Bill" />-->
</form><!-- /#search -->

	</div><!-- /#header -->

	<div id="navigation" >
	<ul class="bottom">
		<li><a href="/Documents/find.htm">Legislators</a>
			<ul>
				<li><a href="/asp/roster/roster.asp">By Session (1896-Current)</a></li>
				<li><a href="/asp/roster/complist.asp">Alphabetical (Historical)</a></li> 
				<li><a href="/GIS/findDistrict.jsp">Find by Address/Map</a></li> 
				<li><a href="/Documents/find.htm">More</a></li>
			</ul>
		</li>
		<li><a href="/Documents/bills.htm">Bills</a>
        	<ul>
            	<li><a href="/asp/billsintro/index.asp">Bills/Bill Requests</a></li>
                <li><a href="/asp/passedbills/passedbills.asp">Passed Bills</a></li>
                <li><a href="/DynaBill/BillList?session=2017GS">2017 Bills</a></li>
                <!--<li><a href="/asp/billtrack/newbills.asp">New Bills/Bill Requests</a></li>-->
                <li><a href="/solrsearch.jsp?ktype=Bill">Keyword Search</a></li>
                <li><a href="/calendar">Reading Calendars</a></li>
                <li><a href="/asp/billtrack/track.asp">Tracking Service</a></li>
                <li><a href="/Documents/bills.htm">More</a></li>
            </ul>
        </li>
		<li><a href="/asp/interim/Main.asp">Committees</a>
			<ul>
				<li><a href="/asp/interim/Main.asp?ComType=All&List=2#Results">All Committees</a></li>
				<li><a href="/asp/interim/Main.asp?ComType=App&List=2#Results">Appropriations</a></li> 
				<li><a href="/asp/interim/Main.asp?ComType=Com&List=2#Results">Commissions</a></li>
                <!--<li><a href="/asp/interim/Commit.asp?Year=2013&Com=SPEILE">Independent Legislative Ethics Commission</a></li>-->
                <li><a href="/documents/EthicsInformation.htm">Independent Legislative Ethics Commission</a></li>
				<li><a href="/asp/interim/Main.asp?ComType=Int&List=2#Results">Interim</a></li>
				<li><a href="/asp/interim/Main.asp?ComType=Std&List=2#Results">Standing</a></li>
				<li><a href="/asp/interim/Main.asp?ComType=Sub&List=2#Results">Subcommittees</a></li>
				<li><a href="/asp/interim/Main.asp?ComType=Tsk&List=2#Results">Task Forces</a></li>
				<li><a href="/asp/billsintro/committeebills.asp">Bills In Committees</a></li>
                
			</ul>
		</li>
		
		<li><a href="/Documents/code_const.htm">Utah Code / Constitution</a>
			<ul>
			   <!--<li><a href="/UtahCode/title.jsp">Title/Chapter/Section</a></li>-->
               <li><a href="/xcode/code.html">Title/Chapter/Section</a></li>
			   <li><a href="/solrsearch.jsp?ktype=Code">Keyword Search </a></li>
			   <!--<li><a href="/UtahCode/chapter.jsp?code=Constitution">Utah Constitution </a></li>-->
               <li><a href="/xcode/constitution.html">Utah Constitution</a></li>
			   <li><a href="http://pioneer.utah.gov/research/databases/utahlaws.html">Laws of Utah 1851-ongoing</a></li>
               <li><a href="http://content.lib.utah.edu/cdm4/browse.php?CISOROOT=/uthisstat">Utah Territorial Laws </a></li>
               <li><a href="/Documents/code_const.htm">More</a></li>
			</ul>
		</li>
		<li><a href="http://senate.utah.gov">Senate</a>
			<ul>
				<li><a href="http://senate.utah.gov">Main Page </a></li>
                		<li><a href="http://senate.utah.gov/about/about-senate.html">About The Senate </a></li>
                		<li><a href="http://senate.utah.gov/senators/leadership.html">Leadership </a></li>
				<li><a href="http://senate.utah.gov/senators/full-roster.html">Roster </a></li>
				<li><a href="/asp/seating/sseat.asp">Seating Chart </a></li>
				<li><a href="/GIS/findDistrict.jsp">District Maps </a></li>
                		<li><a href="/session/extraordinarysessions/es.htm">Extraordinary Sessions </a></li>
				<li><a href="/FloorCalendars/">Reading Calendars </a></li>
				<li><a href="/asp/audio/index.asp?House=S">Past Floor Debates </a></li>
				<li><a href="/documents/journals.htm">Senate Journals </a></li>
				
				
			</ul>
		</li>
		<li><a href="http://house.utah.gov/">House</a>
			<ul>
				<li><a href="http://house.utah.gov/">Main Page</a></li>
				<li><a href="http://house.utah.gov/about/">About the House </a></li>
                		<li><a href="http://house.utah.gov/house-leadership/">Leadership </a></li>
				<li><a href="http://house.utah.gov/house-members/">Roster </a></li>
				<li><a href="/asp/seating/hseat.asp">Seating Chart </a></li>
				<li><a href="/GIS/findDistrict.jsp">District Maps </a></li>
				<li><a href="/FloorCalendars/">Reading Calendars </a></li>
				<li><a href="/asp/audio/index.asp?House=H">Past Floor Debates </a></li>
				<li><a href="/documents/journals.htm">Journals </a></li>
				<li><a href="http://house.utah.gov/conflict-disclosures/">Conflict of Interest Forms </a></li>
				
			</ul>
		</li>
		<li><a href="/lrgc/civiceducation.htm">Legislative Guide </a>
			<ul>
				<li><a href="/lrgc/civiceducation.htm">Legislative Guide</a></li>
				<li><a href="/lrgc/civicProgram.htm">Civic Programs</a></li>
                <li><a href="/Documents/recordsrequests.htm">GRAMA (Records Requests)</a></li>
                
			</ul>
		</li>
	<li><a href="/documents/publications.htm">Publications</a>
        	<ul class="bottom">
            	<li><a href="/Publications/PubSearch">Search Publications</a></li>
                <li><a href="/asp/lfa/lfareports.asp">Appropriations</a></li>
                <li><a href="/audit/ad_alldl.htm">Audits</a></li>
                <li><a href="/lrgc/briefings/bagelsbriefings.htm">Bagels & Briefings</a></li>
                <li><a href="/lrgc/briefings/briefingpapers.htm">Briefing Papers</a></li>
                <li><a href="/session/2014/pdfdoc/Digest2014.pdf">Digest of Legislation</a></li>
                <li><a href="/documents/LDM/draftingManual.html">Legislative Drafting Manual</a></li>
                <!--<li><a href="/documents/journals.htm">Journals</a></li>-->
				<li><a href="/asp/schedule/journal.asp">Journals</a></li>
                <!--<li><a href="/Documents/InterimHighlights.htm">Interim Highlights</a></li>-->
                <li><a href="/lrgc/interimHighlights.jsp">Interim Highlights</a></li>
                <!--<li><a href="/URC/drules.jsp">Legislative Rules</a></li>-->
                <li><a href="/xcode/R.html">Legislative Rules</a></li>
                <li><a href="/Documents/recordsrequests.htm">GRAMA (Records Requests)</a></li>
                <li><a href="/publicweb/menu.jsp">Public Email</a></li>
                <li><a href="/lrgc/stateorganizationcharts2016.pdf">State Organization Charts</a></li>
                <li><a href="https://www.youtube.com/user/UtahLegislature" target="_blank" title="Utah Legislature YouTube channel">YouTube Channel</a></li>
                <li><a href="/rfp_legal.htm">Requests for Proposals and Legal Notices</a></li>
                <li><a href="/documents/publications.htm">More</a></li>
            </ul>
        </li>
		<li><a href="/Documents/legislative.htm#histories">Legislative Histories</a>
        	<ul class="bottom">
                <li><a href="/lrgc/legislativehistoryresources.htm">Legislative History Resources</a></li>
                <li><a href="http://archives.utah.gov/research/guides/legislative-history.htm">How to Research</a></li>
                <li><a href="http://image.le.utah.gov/imaging/bill.asp">Bill Drafting/Research Files (1990-Ongoing)</a></li>
                <!--<li><a href="http://images.archives.utah.gov/cdm/search/collection/432">Working Bills (1896-1989)</a></li>-->
                <li><a href="http://images.archives.utah.gov/cdm/search/collection/432n!428/searchterm/working%20bills/field/all/mode/all/conn/and/order/identi/ad/asc">Working Bills (1896-1989)</a></li>
                <li><a href="http://image.le.utah.gov/imaging/History.asp">Interim Committee Histories (1990-Ongoing) </a></li>
                <li><a href="/documents/journals.htm">Journals</a></li>
                <li><a href="/asp/audio/index.asp?House=H">Past House Floor Debates</a></li>
                <li><a href="/asp/audio/index.asp?House=S">Past Senate Floor Debates</a></li>
                <li><a href="/Documents/legislative.htm#histories">More</a></li>
            </ul>
        </li>
		<li><a href="/Documents/staff.htm">Staff Offices</a>
        	<ul class="bottom">
            	<li><a href="/LegislativeOffices.htm">All Legislative Offices</a></li>
                <li><a href="/audit/olag.htm">Auditor General</a></li>
                <li><a href="/lfa/index.htm">Fiscal Analyst</a></li>
                <li><a href="/printing/index.htm">Legislative Printing and Billroom</a></li>
                <li><a href="/lrgc/lrgc.htm">Research and General Counsel</a></li>
                <li><a href="/ncsl/utahstaffawards.htm">Staff Awards</a></li>
                <li><a href="/jobs/jobs.htm">Job Opportunities</a></li>
                <li><a href="/Documents/staff.htm">More</a></li>
            </ul>
        </li>
		<li><a href="/Documents/linksofinterest.htm">Links of Interest</a>
        	<ul class="bottom">
            	<li><a href="http://www.rules.utah.gov/">Utah Administrative Rules</a></li>
                <li><a href="http://www.utcourts.gov">Courts</a></li>
                <li><a href="http://www.utahstatecapitol.utah.gov/">Utah State Capitol</a></li>
                <li><a href="http://www.utah.gov">State of Utah</a></li>
                <li><a href="http://thomas.loc.gov">Federal Legislation</a></li>
                <li><a href="/Documents/linksofinterest.htm">More</a></li>
            </ul>
        </li>
	</ul>
</div><!-- /#navigation -->


  <div id="main">	
	
    <div id="content">
    <a class="right printbtn" href="#" onClick="applyPrintStyle()" title="Toggle printer friendly view">&nbsp;</a>
   
<BODY BACKGROUND="/images/bk/lrgcbk2.jpg"><BR>
Download Zipped Introduced WP 6.1 <a href="/~1998/bills/hbillint/HB0309.zip">HB0309.ZIP</a> 20,965 Bytes<br>
<a href="/~1998/status/hbillsta/HB0309.txt">[Status]</a><a href="/~1998/htmdoc/hbillhtm/HB0309.htm">[Bill Documents]</a><a href="/lfa/fnotes/1998/HB0309.pdf">[Fiscal Note]</a><a href="/~1998/bills.htm">[Bills Directory]</a>
<hr>
<p>
<H3>H.B. 309</H3>
<p>

<!-- File converted by Wp2Html Version 2.4e  -->
<!-- Email Andy.Scriven@research.natpower.co.uk for more details  -->

<!-- WP Style Open: System_34 --><!-- WP Style End: System_34 -->

<!-- Font changed to TimesNewRomanRegular with size 13 -->
1&nbsp;&nbsp;&nbsp;&nbsp;<center><b> CONTROLLED SUBSTANCES ACT</b></center>

<br>

2&nbsp;&nbsp;&nbsp;&nbsp;<b> <center>AMENDMENTS</b>
<!-- End of font TimesNewRomanRegular with size 13 -->
<!-- Font changed to TimesNewRomanRegular with size 12 --></center>

<br>

3&nbsp;&nbsp;&nbsp;&nbsp;<center>1998 GENERAL SESSION</center>

<br>

4&nbsp;&nbsp;&nbsp;&nbsp;<center>STATE OF UTAH</center>

<br>

5&nbsp;&nbsp;&nbsp;&nbsp;<center><b> Sponsor: Patrice Arent</b></center>

<br>

6&nbsp;&nbsp;&nbsp;&nbsp;AN ACT RELATING TO CONTROLLED SUBSTANCES; AMENDING THE CONTROLLED<br>

7&nbsp;&nbsp;&nbsp;&nbsp;SUBSTANCES ACT TO REFLECT THE FEDERAL CODE IN SCHEDULES I THROUGH<br>

8&nbsp;&nbsp;&nbsp;&nbsp;V; AND PROVIDING AN INFORMATIONAL NOTE.<br>

9&nbsp;&nbsp;&nbsp;&nbsp;This act affects sections of Utah Code Annotated 1953 as follows:<br>

10&nbsp;&nbsp;&nbsp;&nbsp;AMENDS:<br>

11&nbsp;&nbsp;&nbsp;&nbsp;<b> &nbsp;&nbsp;&nbsp;&nbsp;58-37-4</b>, as last amended by Chapter 64, Laws of Utah 1997<br>

12&nbsp;&nbsp;&nbsp;&nbsp;This act enacts uncodified material.<br>

13&nbsp;&nbsp;&nbsp;&nbsp;<i>Be it enacted by the Legislature of the state of Utah:</i><br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.  Section <b> <b>58-37-4</b></b> is amended to read:<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b> 58-37-4.</b>   <b> Schedules of controlled substances -- Schedules I through V -- Findings</b><br>

16&nbsp;&nbsp;&nbsp;&nbsp;<b> required -- Specific substances included in schedules.</b><br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)  There are established five schedules of controlled substances known as Schedules I,<br>

18&nbsp;&nbsp;&nbsp;&nbsp;II, III, IV, and V which shall consist of substances listed in this section.<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)  Schedules I, II, III, IV, and V consist of the following drugs or other substances by the<br>

20&nbsp;&nbsp;&nbsp;&nbsp;official name, common or usual name, chemical name, or brand name designated:<br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  Schedule I:<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  Unless specifically excepted or unless listed in another schedule, any of the following<br>

23&nbsp;&nbsp;&nbsp;&nbsp;opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when<br>

24&nbsp;&nbsp;&nbsp;&nbsp;the existence of the isomers, esters, ethers, and salts is possible within the specific chemical<br>

25&nbsp;&nbsp;&nbsp;&nbsp;designation:<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  [<strike>Acetyl-alphamethylfentanyl</strike>] <u><i>Acetyl-alpha-methylfentanyl</i></u><br>

27&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide)</i></u>;
<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Acetylmethadol;<br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Allylprodine;<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Alphacetylmethadol<u><i>,</i></u> [<strike>(</strike>]except levo-alphacetylmethadol also known as<br>

4&nbsp;&nbsp;&nbsp;&nbsp;<u><i>levo-</i></u>alpha-acetylmethadol, levomethadyl acetate, or LAAM[<strike>)</strike>];<br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Alphameprodine;<br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Alphamethadol;<br>

7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(G)  Alpha-methiofentanyl;</strike>]<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(H)</strike>] <u><i>(G)</i></u>  Alpha-methylfentanyl <u><i>(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]</i></u><br>

9&nbsp;&nbsp;&nbsp;&nbsp;<u><i>propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N- propanilido) piperidine)</i></u>;<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(H)  Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-</i></u><br>

11&nbsp;&nbsp;&nbsp;&nbsp;<u><i>piperidinyl]-N-phenylpropanamide);</i></u><br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Benzethidine;<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(L)</strike>] <u><i>(J)</i></u>  Betacetylmethadol;<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Beta-hydroxyfentanyl <u><i>(N-[1-(2-hydroxy-2-phenethyl)-4-</i></u><br>

15&nbsp;&nbsp;&nbsp;&nbsp;<u><i>piperidinyl]-N-phenylpropanamide)</i></u>;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(J)</strike>] <u><i>(L)</i></u>  Beta-hydroxy-3-methylfentanyl<u><i>, other name: N-[1-(2-hydroxy-2-</i></u><br>

17&nbsp;&nbsp;&nbsp;&nbsp;<u><i>phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide</i></u>;<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  Betameprodine;<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Betamethadol;<br>

20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(O)  Betaprodine;<br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(P)  Cathinone;</strike>]<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Q)</strike>] <u><i>(P)</i></u>  Clonitazene;<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(R)</strike>] <u><i>(Q)</i></u>  Dextromoramide;<br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(S)</strike>] <u><i>(R)</i></u>  Diampromide;<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(T)</strike>] <u><i>(S)</i></u>  Diethylthiambutene;<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(U)</strike>] <u><i>(T)</i></u>  Difenoxin;<br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(V)</strike>] <u><i>(U)</i></u>  Dimenoxadol;<br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(W)</strike>] <u><i>(V)</i></u>  Dimepheptanol;<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(X)</strike>] <u><i>(W)</i></u>  Dimethylthiambutene;<br>

30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Y)</strike>] <u><i>(X)</i></u>  Dioxaphetyl butyrate;<br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Z)</strike>] <u><i>(Y)</i></u>  Dipipanone;<br>
<br>
<center>- 2 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(AA)</strike>] <u><i>(Z)</i></u>  Ethylmethylthiambutene;<br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(BB)</strike>] <u><i>(AA)</i></u>  Etonitazene;<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(CC)</strike>] <u><i>(BB)</i></u>  Etoxeridine;<br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(DD)</strike>] <u><i>(CC)</i></u>  Furethidine;<br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(EE)</strike>] <u><i>(DD)</i></u>  Hydroxypethidine;<br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(FF)</strike>] <u><i>(EE)</i></u>  Ketobemidone;<br>

7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(GG)</strike>] <u><i>(FF)</i></u>  Levomoramide;<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(HH)</strike>] <u><i>(GG)</i></u>  Levophenacylmorphan;<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(II)  Methcathinone;</strike>]<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(JJ)</strike>] <u><i>(HH)</i></u>  Morpheridine;<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(KK)</strike>] <u><i>(II)</i></u>  [<strike>Mppp (l-methyl-4-phenyl-4-propionoxpipiridine)</strike>] <u><i>MPPP</i></u><br>

12&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(1-methyl-4-phenyl-4-propionoxypiperidine)</i></u>;<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(LL)</strike>] <u><i>(JJ)</i></u>  Noracymethadol;<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(MM)</strike>] <u><i>(KK)</i></u>  Norlevorphanol;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(NN)</strike>] <u><i>(LL)</i></u>  Normethadone;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(OO)</strike>] <u><i>(MM)</i></u>  Norpipanone;<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(PP)</strike>] <u><i>(NN)</i></u>  Para-fluorofentanyl <u><i>(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]</i></u><br>

18&nbsp;&nbsp;&nbsp;&nbsp;<u><i>propanamide</i></u>;<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(QQ)</strike>] <u><i>(OO)</i></u>  PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);<br>

20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(RR)</strike>] <u><i>(PP)</i></u>  Phenadoxone;<br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(SS)</strike>] <u><i>(QQ)</i></u>  Phenampromide;<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(TT)</strike>] <u><i>(RR)</i></u>  Phenomorphan;<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(UU)</strike>] <u><i>(SS)</i></u>  Phenoperidine;<br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(VV)</strike>] <u><i>(TT)</i></u>  Piritramide;<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(WW)</strike>] <u><i>(UU)</i></u>  Proheptazine;<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(XX)</strike>] <u><i>(VV)</i></u>  Properidine;<br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(YY)</strike>] <u><i>(WW)</i></u>  Propiram;<br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(ZZ)</strike>] <u><i>(XX)</i></u>  Racemoramide;<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(AAA)</strike>] <u><i>(YY)</i></u>  Thiofentanyl <u><i>(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide</i></u>;<br>

30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(BBB)</strike>] <u><i>(ZZ)</i></u>  Tilidine;<br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(CCC)</strike>] <u><i>(AAA)</i></u>  Trimeperidine;<br>
<br>
<center>- 3 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(DDD)  3-menthylthiofentanyl; and</strike>]<br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(EEE)</strike>] <u><i>(BBB)</i></u>  3-methylfentanyl[<strike>.</strike>]<u><i>, including the optical and geometric isomers</i></u><br>

3&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and</i></u><br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(CCC)  3-methylthiofentanyl</i></u><br>

5&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).</i></u><br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  Unless specifically excepted or unless listed in another schedule, any of the following<br>

7&nbsp;&nbsp;&nbsp;&nbsp;opium derivatives, their salts, isomers, and salts of isomers when the existence of the salts,<br>

8&nbsp;&nbsp;&nbsp;&nbsp;isomers, and salts of isomers is possible within the specific chemical designation:<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Acetorphine;<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Acetyldihydrocodeine;<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Benzylmorphine;<br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Codeine methylbromide;<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Codeine-N-Oxide;<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Cyprenorphine;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Desomorphine;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Dihydromorphine;<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Drotebanol;<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Etorphine (except hydrochloride salt);<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Heroin;<br>

20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(L)  Hydromorphinol;<br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  Methyldesorphine;<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Methylhydromorphine;<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(O)  Morphine methylbromide;<br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(P)  Morphine methylsulfonate;<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Q)  Morphine-N-Oxide;<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(R)  Myrophine;<br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(S)  Nicocodeine;<br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(T)  Nicomorphine;<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(U)  Normorphine;<br>

30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(V)  Pholcodine; and<br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(W)  Thebacon.<br>
<br>
<center>- 4 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  Unless specifically excepted or unless listed in another schedule, any material,<br>

2&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following hallucinogenic<br>

3&nbsp;&nbsp;&nbsp;&nbsp;substances, or which contains any of their salts, isomers, and salts of isomers when the existence<br>

4&nbsp;&nbsp;&nbsp;&nbsp;of the salts, isomers, and salts of isomers is possible within the specific chemical designation; as<br>

5&nbsp;&nbsp;&nbsp;&nbsp;used in this Subsection <u><i>(2)</i></u>(iii) only, &quot;isomer&quot; includes the optical, position, and geometric<br>

6&nbsp;&nbsp;&nbsp;&nbsp;isomers:<br>

7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(A)  Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;</i></u><br>

8&nbsp;&nbsp;&nbsp;&nbsp;<u><i>.-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; .-ET; and AET;</i></u><br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(A)</strike>] <u><i>(B)</i></u>  4-bromo-2,5-dimethoxy-amphetamine<u><i>, some trade or other names:</i></u><br>

10&nbsp;&nbsp;&nbsp;&nbsp;<u><i>4-bromo-2,5-dimethoxy-.-methylphenethylamine; 4-bromo-2,5-DMA</i></u>;<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(C)  4-bromo-2,5-dimethoxypenethylamine, some trade or other names:</i></u><br>

12&nbsp;&nbsp;&nbsp;&nbsp;<u><i>2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;</i></u><br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(B)</strike>] <u><i>(D)</i></u>  2,5-dimethoxyamphetamine<u><i>, some trade or other names:</i></u><br>

14&nbsp;&nbsp;&nbsp;&nbsp;<u><i>2,5-dimethoxy-.-methylphenethylamine; 2,5-DMA</i></u>;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(E)  2,5-dimethoxy-4-ethylamphet-amine, some trade or other names: DOET;</i></u><br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  4-methoxyamphetamine<u><i>, some trade or other names:</i></u><br>

17&nbsp;&nbsp;&nbsp;&nbsp;<u><i>4-methoxy-.-methylphenethylamine; paramethoxyamphetamine, PMA</i></u>;<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(E)</strike>] <u><i>(G)</i></u>  5-methoxy-3,4-methylenedioxy amphetamine;<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(K)</strike>] <u><i>(H)</i></u>  4-methyl-2,5-dimethoxy-amphetamine<u><i>, some trade and other names:</i></u><br>

20&nbsp;&nbsp;&nbsp;&nbsp;<u><i>4-methyl-2,5-dimethoxy-.-methylphenethylamine; &quot;DOM&quot;; and &quot;STP&quot;</i></u>;<br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(C)</strike>] <u><i>(I)</i></u>  3,4-methylenedioxy amphetamine;<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(D)  3,4-methylenedioxy methamphetamine (MDMA);</strike>]<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(J)  3,4-methylenedioxymethamphetamine (MDMA);</i></u><br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(K)  3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-</i></u><br>

25&nbsp;&nbsp;&nbsp;&nbsp;<u><i>alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA,  MDE, MDEA;</i></u><br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(L)  N-hydroxy-3,4-methylenedioxyamphetamine, also known as</i></u><br>

27&nbsp;&nbsp;&nbsp;&nbsp;<u><i>N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;</i></u><br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(G)</strike>] <u><i>(M)</i></u>  3,4,5-trimethoxy amphetamine;<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(H)</strike>] <u><i>(N)</i></u>  Bufotenine<u><i>, some trade and other names: 3-(.</i></u><br>

30&nbsp;&nbsp;&nbsp;&nbsp;<u><i>-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,</i></u><br>

31&nbsp;&nbsp;&nbsp;&nbsp;<u><i>N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine</i></u>;<br>
<br>
<center>- 5 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(I)</strike>] <u><i>(O)</i></u>  Diethyltryptamine<u><i>, some trade and other names: N,N-Diethyltryptamine; DET</i></u>;<br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(J)</strike>] <u><i>(P)</i></u>  Dimethyltryptamine<u><i>, some trade or other names: DMT</i></u>;<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(L)</strike>] <u><i>(Q)</i></u>  Ibogaine<u><i>, some trade and other names:</i></u><br>

4&nbsp;&nbsp;&nbsp;&nbsp;<u><i>7-Ethyl-6,6.,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino</i></u><br>

5&nbsp;&nbsp;&nbsp;&nbsp;<u><i>[5,4-b] indole; Tabernanthe iboga</i></u>;<br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(M)</strike>] <u><i>(R)</i></u>  Lysergic acid diethylamide;<br>

7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(N)</strike>] <u><i>(S)</i></u>  [<strike>Marijuana</strike>] <u><i>Marihuana;</i></u>;<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(O)</strike>] <u><i>(T)</i></u>  Mescaline;<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(P)</strike>] <u><i>(U)</i></u>  Parahexyl<u><i>, some trade or other names:</i></u><br>

10&nbsp;&nbsp;&nbsp;&nbsp;<u><i>3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl</i></u>;<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Q)</strike>] <u><i>(V)</i></u>  Peyote<u><i>, meaning all parts of the plant presently classified botanically as</i></u><br>

12&nbsp;&nbsp;&nbsp;&nbsp;<u><i>Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any</i></u><br>

13&nbsp;&nbsp;&nbsp;&nbsp;<u><i>part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of</i></u><br>

14&nbsp;&nbsp;&nbsp;&nbsp;<u><i>such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12))</i></u>;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(R)</strike>] <u><i>(W)</i></u>  N-ethyl-3-piperidyl benzilate;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(S)</strike>] <u><i>(X)</i></u>  N-methyl-3-piperidyl benzilate;<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(T)</strike>] <u><i>(Y)</i></u>  Psilocybin;<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(U)</strike>] <u><i>(Z)</i></u>  Psilocyn;<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(V)</strike>] <u><i>(AA)</i></u>  Tetrahydrocannabinols<u><i>, synthetic equivalents of the substances contained in</i></u><br>

20&nbsp;&nbsp;&nbsp;&nbsp;<u><i>the plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,</i></u><br>

21&nbsp;&nbsp;&nbsp;&nbsp;<u><i>and their isomers with similar chemical structure and pharmacological activity such as the</i></u><br>

22&nbsp;&nbsp;&nbsp;&nbsp;<u><i>following: .1 cis or trans tetrahydrocannabinol, and their optical isomers   .6 cis or trans</i></u><br>

23&nbsp;&nbsp;&nbsp;&nbsp;<u><i>tetrahydrocannabinol, and their optical isomers .3,4 cis or trans tetrahydrocannabinol, and its</i></u><br>

24&nbsp;&nbsp;&nbsp;&nbsp;<u><i>optical isomers, and since nomenclature of these substances is not internationally standardized,</i></u><br>

25&nbsp;&nbsp;&nbsp;&nbsp;<u><i>compounds of these structures, regardless of numerical designation of atomic positions covered</i></u>;<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(W)</strike>] <u><i>(BB)</i></u>  Ethylamine analog of phencyclidine<u><i>, some trade or other names:</i></u><br>

27&nbsp;&nbsp;&nbsp;&nbsp;<u><i>N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,</i></u><br>

28&nbsp;&nbsp;&nbsp;&nbsp;<u><i>N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE</i></u>;<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(X)</strike>] <u><i>(CC)</i></u>  Pyrrolidine analog of phencyclidine<u><i>, some trade or other names:</i></u><br>

30&nbsp;&nbsp;&nbsp;&nbsp;<u><i>1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP</i></u>;<br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Y)  1-1-(2-Thieny) Cyclohexyl Pyrrolidine; and</strike>]<br>
<br>
<center>- 6 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Z)</strike>] <u><i>(DD)</i></u>  Thiophene analog of phencyclidine[<strike>.</strike>]<u><i>, some trade or other names:</i></u><br>

2&nbsp;&nbsp;&nbsp;&nbsp;<u><i>1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and</i></u><br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(EE)  1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.</i></u><br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  Unless specifically excepted or unless listed in another schedule, any material<br>

5&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances having<br>

6&nbsp;&nbsp;&nbsp;&nbsp;a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers<br>

7&nbsp;&nbsp;&nbsp;&nbsp;when the existence of the salts, isomers, and salts of isomers is possible within the specific<br>

8&nbsp;&nbsp;&nbsp;&nbsp;chemical designation:<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Mecloqualone; and<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Methaqualone.<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  Any material, compound, mixture, or preparation containing any quantity of the<br>

12&nbsp;&nbsp;&nbsp;&nbsp;following substances having a stimulant effect on the central nervous system, including their salts,<br>

13&nbsp;&nbsp;&nbsp;&nbsp;isomers, and salts of isomers:<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(A)  Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or</i></u><br>

15&nbsp;&nbsp;&nbsp;&nbsp;<u><i>4,5-dihydro-5-phenly-2-oxazolamine;</i></u><br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(B)  Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,</i></u><br>

17&nbsp;&nbsp;&nbsp;&nbsp;<u><i>alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;</i></u><br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(A)</strike>] <u><i>(C)</i></u>  Fenethylline;<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(D)  Methcathinone, some other names: 2-(methylamino)-propiophenone;</i></u><br>

20&nbsp;&nbsp;&nbsp;&nbsp;<u><i>alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;</i></u><br>

21&nbsp;&nbsp;&nbsp;&nbsp;<u><i>alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;</i></u><br>

22&nbsp;&nbsp;&nbsp;&nbsp;<u><i>methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of</i></u><br>

23&nbsp;&nbsp;&nbsp;&nbsp;<u><i>optical isomers;</i></u><br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(B)  4-Methylaminorex; and</strike>]<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(E)  (.)cis-4-methylaminorex ((.)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);</i></u><br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(C)</strike>] <u><i>(F)</i></u>  N-ethylamphetamine<u><i>; and</i></u><br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(G)  N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine;</i></u><br>

28&nbsp;&nbsp;&nbsp;&nbsp;<u><i>N,N-alpha-trimethylphenethylamine</i></u>.<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(vi)  Any material, compound, mixture, or preparation which contains any quantity of the</i></u><br>

30&nbsp;&nbsp;&nbsp;&nbsp;<u><i>following substances, including their optical isomers, salts, and salts of isomers, subject to</i></u><br>

31&nbsp;&nbsp;&nbsp;&nbsp;<u><i>temporary emergency scheduling:</i></u><br>
<br>
<center>- 7 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(A)  N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and</i></u><br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(B)  N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).</i></u><br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  Schedule II:<br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  Unless specifically excepted or unless listed in another schedule, any of the following<br>

5&nbsp;&nbsp;&nbsp;&nbsp;substances whether produced directly or indirectly by extraction from substances of vegetable<br>

6&nbsp;&nbsp;&nbsp;&nbsp;origin, or independently by means of chemical synthesis, or by a combination of extraction and<br>

7&nbsp;&nbsp;&nbsp;&nbsp;chemical synthesis:<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Opium and opiate, and any salt, compound, derivative, or preparation of opium or<br>

9&nbsp;&nbsp;&nbsp;&nbsp;opiate, excluding apomorphine, dextrorphan, nalbuphine, <u><i>nalmefene,</i></u> naloxone, and naltrexone,<br>

10&nbsp;&nbsp;&nbsp;&nbsp;and their respective salts, but including:<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Raw opium;<br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(II)  Opium extracts;<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(III)  Opium fluid [<strike>extracts</strike>];<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(IV)  Powdered opium;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(V)  Granulated opium;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(VI)  Tincture of opium;<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(VII)  Codeine;<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(VIII)  Ethylmorphine;<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(IX)  Etorphine hydrochloride;<br>

20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)  Hydrocodone;<br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XI)  Hydromorphone;<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XII)  Metopon;<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XIII)  Morphine;<br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XIV)  Oxycodone;<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XV)  Oxymorphone; and<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(XVI)  Thebaine;<br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Any salt, compound, derivative, or preparation which is chemically equivalent or<br>

28&nbsp;&nbsp;&nbsp;&nbsp;identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these<br>

29&nbsp;&nbsp;&nbsp;&nbsp;substances may not include the isoquinoline alkaloids of opium;<br>

30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Opium poppy and poppy straw;<br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any<br>
<br>
<center>- 8 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;salt, compound, derivative, or preparation which is chemically equivalent or identical with any of<br>

2&nbsp;&nbsp;&nbsp;&nbsp;these substances, and includes cocaine <u><i>and ecgonine</i></u>, [<strike>its</strike>] <u><i>their salts,</i></u> isomers<u><i>, derivatives,</i></u> and salts<br>

3&nbsp;&nbsp;&nbsp;&nbsp;of isomers <u><i>and derivatives</i></u>, whether derived from the coca plant or synthetically produced, except<br>

4&nbsp;&nbsp;&nbsp;&nbsp;the substances may not include decocainized coca leaves or extraction of coca leaves, which<br>

5&nbsp;&nbsp;&nbsp;&nbsp;extractions do not contain cocaine or ecgonine; and<br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Concentrate of poppy straw, which means the crude extract of poppy straw in either<br>

7&nbsp;&nbsp;&nbsp;&nbsp;liquid, solid, or powder form which contains the [<strike>phenanthrine</strike>] <u><i>phenanthrene</i></u> alkaloids of the<br>

8&nbsp;&nbsp;&nbsp;&nbsp;opium poppy.<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  Unless specifically excepted or unless listed in another schedule, any of the following<br>

10&nbsp;&nbsp;&nbsp;&nbsp;opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when<br>

11&nbsp;&nbsp;&nbsp;&nbsp;the existence of the isomers, esters, ethers, and salts is possible within the specific chemical<br>

12&nbsp;&nbsp;&nbsp;&nbsp;designation, except dextrorphan <u><i>and levopropoxyphene</i></u>:<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(B)</strike>] <u><i>(A)</i></u>  Alfentanil;<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(A)</strike>] <u><i>(B)</i></u>  Alphaprodine;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Anileridine;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Bezitramide;<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Bulk dextropropoxyphene (nondosage forms);<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Carfentanil;<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Dihydrocodeine;<br>

20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Diphenoxylate;<br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Fentanyl;<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Isomethadone;<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(L)</strike>] <u><i>(K)</i></u>  Levo-alphacetylmethadol<u><i>,</i></u> [<strike>(</strike>]some other names: <u><i>levo-</i></u>alpha-acetylmethadol,<br>

24&nbsp;&nbsp;&nbsp;&nbsp;levomethadyl acetate, or LAAM[<strike>)</strike>];<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(K)</strike>] <u><i>(L)</i></u>  Levomethorphan;<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(M)  Levorphanol;<br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(N)  Metazocine;<br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(O)  Methadone;<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(P)  Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;<br>

30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Q)  Methyl-Fentanyl;</strike>]<br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(R)</strike>] <u><i>(Q)</i></u>  Moramide-Intermediate, 2-methyl-3-morpholino-1,<br>
<br>
<center>- 9 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;1-diphenylpropane-carboxylic acid;<br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(S)</strike>] <u><i>(R)</i></u>  Pethidine (meperidine);<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(T)</strike>] <u><i>(S)</i></u>  Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;<br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(U)</strike>] <u><i>(T)</i></u>  Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;<br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(V)</strike>] <u><i>(U)</i></u>  Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;<br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(W)</strike>] <u><i>(V)</i></u>  Phenazocine;<br>

7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(X)</strike>] <u><i>(W)</i></u>  Piminodine;<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Y)</strike>] <u><i>(X)</i></u>  Racemethorphan;<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Z)</strike>] <u><i>(Y)</i></u>   Racemorphan; [<strike>and</strike>]<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(Z)  Remifentanil; and</i></u><br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(AA)  Sufentanil.<br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  Unless specifically excepted or unless listed in another schedule, any material,<br>

13&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances having<br>

14&nbsp;&nbsp;&nbsp;&nbsp;a stimulant effect on the central nervous system:<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Amphetamine, its salts, optical isomers, and salts of its optical isomers;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Methamphetamine, its salts, isomers, and salts of its isomers;<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Phenmetrazine and its salts; and<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Methylphenidate.<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  Unless specifically excepted or unless listed in another schedule, any material,<br>

20&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances having<br>

21&nbsp;&nbsp;&nbsp;&nbsp;a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers<br>

22&nbsp;&nbsp;&nbsp;&nbsp;when the existence of the salts, isomers, and salts of isomers is possible within the specific<br>

23&nbsp;&nbsp;&nbsp;&nbsp;chemical designation:<br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Amobarbital;<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(B)  N,N,Dimethylamphetamine;</strike>]<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(C)</strike>] <u><i>(B)</i></u>  Glutethimide;<br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(D)</strike>] <u><i>(C)</i></u>  Pentobarbital;<br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(E)</strike>] <u><i>(D)</i></u>  Phencyclidine;<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(F)</strike>] <u><i>(E)</i></u>  Phencyclidine immediate precursors: [<strike>1-phenyl-cyclohexylamine</strike>]<br>

30&nbsp;&nbsp;&nbsp;&nbsp;<u><i>1-phenylcyclohexylamine</i></u> and 1-piperidinocyclohexanecarbonitrile (PCC); and<br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(G)</strike>] <u><i>(F)</i></u>  Secobarbital.<br>
<br>
<center>- 10 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  Unless specifically excepted or unless listed in another schedule, any material,<br>

2&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of Phenylacetone.<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some of these substances may be known by trade or other names: phenyl-2-propanone,<br>

4&nbsp;&nbsp;&nbsp;&nbsp;P2P; benzyl methyl ketone, methyl benzyl ketone.<br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) (A)  [<strike>Dranabinol</strike>] <u><i>Dronabinol</i></u> (synthetic) in sesame oil and encapsulated in a soft<br>

6&nbsp;&nbsp;&nbsp;&nbsp;gelatin capsule in a [<strike>Fulnal</strike>] <u><i>U.S.</i></u> Food and Drug Administration approved drug product<u><i>, some</i></u><br>

7&nbsp;&nbsp;&nbsp;&nbsp;<u><i>other names for dronabinol:</i></u><br>

8&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or</i></u><br>

9&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(-)-delta-9-(trans)-tetrahydrocannabinol</i></u>; and<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  [<strike>Nabinol</strike>] <u><i>Nabilone, another name for nabilone:</i></u><br>

11&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(.)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,</i></u><br>

12&nbsp;&nbsp;&nbsp;&nbsp;<u><i>6-dimethyl-9H-dibenzo[b,d]pyran-9-one</i></u>.<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)  Schedule III:<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  Unless specifically excepted or unless listed in another schedule, any material,<br>

15&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances having<br>

16&nbsp;&nbsp;&nbsp;&nbsp;a stimulant effect on the central nervous system, including its salts, isomers whether optical,<br>

17&nbsp;&nbsp;&nbsp;&nbsp;position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts<br>

18&nbsp;&nbsp;&nbsp;&nbsp;of isomers is possible within the specific chemical designation:<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Those compounds, mixtures, or preparations in dosage unit form containing any<br>

20&nbsp;&nbsp;&nbsp;&nbsp;stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed<br>

21&nbsp;&nbsp;&nbsp;&nbsp;on August 25, 1971, as excepted compounds under Section [<strike>308.32</strike>] <u><i>1308.32</i></u> of Title 21 of the<br>

22&nbsp;&nbsp;&nbsp;&nbsp;Code of Federal Regulations, and any other drug of the quantitive composition shown in that list<br>

23&nbsp;&nbsp;&nbsp;&nbsp;for those drugs or which is the same except that it contains a lesser quantity of controlled<br>

24&nbsp;&nbsp;&nbsp;&nbsp;substances;<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Benzphetamine;<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Chlorphentermine;<br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Clortermine; <u><i>and</i></u><br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(E)  Mazindol; and</strike>]<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(F)</strike>] <u><i>(E)</i></u>  Phendimetrazine.<br>

30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  Unless specifically excepted or unless listed in another schedule, any material,<br>

31&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances having<br>
<br>
<center>- 11 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;a depressant effect on the central nervous system:<br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Any compound, mixture, or preparation containing amobarbital, secobarbital,<br>

3&nbsp;&nbsp;&nbsp;&nbsp;pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients which<br>

4&nbsp;&nbsp;&nbsp;&nbsp;are not listed in any schedule;<br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital,<br>

6&nbsp;&nbsp;&nbsp;&nbsp;or any salt of any of these drugs which is approved by the Food and Drug Administration for<br>

7&nbsp;&nbsp;&nbsp;&nbsp;marketing only as a suppository;<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Any substance which contains any quantity of a derivative of barbituric acid or any<br>

9&nbsp;&nbsp;&nbsp;&nbsp;salt of any of them;<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  [<strike>Chorhexadol</strike>] <u><i>Chlorhexadol</i></u>;<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Lysergic acid;<br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Lysergic acid amide;<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Methyprylon;<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Sulfondiethylmethane;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Sulfonethylmethane;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)  Sulfonmethane; and<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(K)  Tiletamine and zolazepam or any of their salts<u><i>, some trade or other names for a</i></u><br>

18&nbsp;&nbsp;&nbsp;&nbsp;<u><i>tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine: </i></u><br>

19&nbsp;&nbsp;&nbsp;&nbsp;<u><i>2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam: </i></u><br>

20&nbsp;&nbsp;&nbsp;&nbsp;<u><i>4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,</i></u><br>

21&nbsp;&nbsp;&nbsp;&nbsp;<u><i>flupyrazapon</i></u>.<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  Nalorphine.<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  Unless specifically excepted or unless listed in another schedule, any material,<br>

24&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation containing limited quantities of any of the following narcotic<br>

25&nbsp;&nbsp;&nbsp;&nbsp;drugs, or [<strike>any</strike>] <u><i>their</i></u> salts [<strike>of any of them</strike>] <u><i>calculated as the free anhydrous base or alkaloid</i></u>:<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams<br>

27&nbsp;&nbsp;&nbsp;&nbsp;per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;<br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams<br>

29&nbsp;&nbsp;&nbsp;&nbsp;per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic<br>

30&nbsp;&nbsp;&nbsp;&nbsp;amounts;<br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more<br>
<br>
<center>- 12 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid<br>

2&nbsp;&nbsp;&nbsp;&nbsp;of opium;<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more<br>

4&nbsp;&nbsp;&nbsp;&nbsp;than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in<br>

5&nbsp;&nbsp;&nbsp;&nbsp;recognized therapeutic amounts;<br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90<br>

7&nbsp;&nbsp;&nbsp;&nbsp;milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized<br>

8&nbsp;&nbsp;&nbsp;&nbsp;therapeutic amounts;<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than<br>

10&nbsp;&nbsp;&nbsp;&nbsp;15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized<br>

11&nbsp;&nbsp;&nbsp;&nbsp;therapeutic amounts;<br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(G)  Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not<br>

13&nbsp;&nbsp;&nbsp;&nbsp;more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in<br>

14&nbsp;&nbsp;&nbsp;&nbsp;recognized therapeutic amounts;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(H)  Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with<br>

16&nbsp;&nbsp;&nbsp;&nbsp;one or more active, non-narcotic ingredients in recognized therapeutic amounts.<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  Unless specifically excepted or unless listed in another schedule, anabolic steroids<br>

18&nbsp;&nbsp;&nbsp;&nbsp;including any of the following or any isomer, ester, salt, or derivative of the following that [<strike>acts</strike><br>

19&nbsp;&nbsp;&nbsp;&nbsp;<strike>in the same manner on the human body</strike>] <u><i>promotes muscle growth</i></u>:<br>

20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(A)  Boldenone;</i></u><br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(B)  Chlorotestosterone (4-chlortestosterone);</i></u><br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(A)</strike>] <u><i>(C)</i></u>  Clostebol;<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(B)  Chorionic gonadotropin;</strike>]<br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(C)  Dehydroclormethyltestosterone;</strike>]<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(D)  Dehydrochlormethyltestosterone;</i></u><br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(E)  Dihydrotestosterone (4-dihydrotestosterone);</i></u><br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(F)  Drostanolone;</i></u><br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(D)</strike>] <u><i>(G)</i></u>  Ethylestrenol;<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(E)  Fluxymesterone;</strike>]<br>

30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(H)  Fluoxymesterone;</i></u><br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(I)  Formebulone (formebolone);</i></u><br>
<br>
<center>- 13 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(F)</strike>] <u><i>(J)</i></u>  Mesterolone;<br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(G)  Methandrenone;</strike>]<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(K)  Methandienone;</i></u><br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(L)  Methandranone;</i></u><br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(M)  Methandriol;</i></u><br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(H)</strike>] <u><i>(N)</i></u>  Methandrostenolone;<br>

7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(I)</strike>] <u><i>(O)</i></u>  Methenolone;<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(J)</strike>] <u><i>(P)</i></u>  Methyltestosterone[<strike>, except when combined with esterified estrogens</strike>];<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(Q)  Mibolerone;</i></u><br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(K)</strike>] <u><i>(R)</i></u>  Nandrolone [<strike>decanoate</strike>];<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(L)  Nandrolone phenpropionate;</strike>]<br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(M)</strike>] <u><i>(S)</i></u>  Norethandrolone;<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(N)</strike>] <u><i>(T)</i></u>  Oxandrolone;<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(O)</strike>] <u><i>(U)</i></u>  Oxymesterone;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(P)</strike>] <u><i>(V)</i></u>  Oxymetholone;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(W)  Stanolone;</i></u><br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Q)</strike>] <u><i>(X)</i></u>  Stanozolol; [<strike>and</strike>]<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(Y)  Testolactone;</i></u><br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(R)</strike>] <u><i>(Z)</i></u>  Testosterone [<strike>propionate.</strike>]<u><i>; and</i></u><br>

20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(AA)  Trenbolone.</i></u><br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anabolic steroids expressly intended for administration through implants to cattle or other<br>

22&nbsp;&nbsp;&nbsp;&nbsp;nonhuman species, and approved by the [<strike>Food and Drug Administration</strike>] <u><i>Secretary of Health and</i></u><br>

23&nbsp;&nbsp;&nbsp;&nbsp;<u><i>Human Services</i></u> for use, may not be classified as a controlled substance.<br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)  Schedule IV:<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  Unless specifically excepted or unless listed in another schedule, any material,<br>

26&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not less<br>

27&nbsp;&nbsp;&nbsp;&nbsp;than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them;<br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  Unless specifically excepted or unless listed in another schedule, any material,<br>

29&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances,<br>

30&nbsp;&nbsp;&nbsp;&nbsp;including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts<br>

31&nbsp;&nbsp;&nbsp;&nbsp;of isomers is possible within the specific chemical designation:<br>
<br>
<center>- 14 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Alprazolam;<br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Barbital;<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Bromazepam;<br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(D)  Butorphanol;</i></u><br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(D)</strike>] <u><i>(E)</i></u>  Camazepam;<br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(E)</strike>] <u><i>(F)</i></u>  Chloral betaine;<br>

7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(F)</strike>] <u><i>(G)</i></u>  Chloral hydrate;<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(G)</strike>] <u><i>(H)</i></u>  Chlordiazepoxide;<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(H)</strike>] <u><i>(I)</i></u>  Clobazam;<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(I)</strike>] <u><i>(J)</i></u>  Clonazepam;<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(J)</strike>] <u><i>(K)</i></u>  Clorazepate;<br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(K)</strike>] <u><i>(L)</i></u>  Clotiazepam;<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(L)</strike>] <u><i>(M)</i></u>  Cloxazolam;<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(M)</strike>] <u><i>(N)</i></u>  Delorazepam;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(N)</strike>] <u><i>(O)</i></u>  Diazepam;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(O)</strike>] <u><i>(P)</i></u>  Estazolam;<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(P)</strike>] <u><i>(Q)</i></u>  Ethchlorvynol;<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Q)</strike>] <u><i>(R)</i></u>  Ethinamate;<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(R)</strike>] <u><i>(S)</i></u>  Ethyl loflazepate;<br>

20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(S)</strike>] <u><i>(T)</i></u>  Fludiazepam;<br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(T)</strike>] <u><i>(U)</i></u>  Flunitrazepam;<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(U)</strike>] <u><i>(V)</i></u>  Flurazepam;<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(V)</strike>] <u><i>(W)</i></u>  Halazepam;<br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(W)</strike>] <u><i>(X)</i></u>  Haloxazolam;<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(X)</strike>] <u><i>(Y)</i></u>  Ketazolam;<br>

26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Y)</strike>] <u><i>(Z)</i></u>  Loprazolam;<br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(Z)</strike>] <u><i>(AA)</i></u>  Lorazepam;<br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(BB)  Lormetazepam;</i></u><br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(AA)</strike>] <u><i>(CC)</i></u>  Mebutamate;<br>

30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(BB)</strike>] <u><i>(DD)</i></u>  Medazepam;<br>

31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(CC)  Medazolam;</strike>]<br>
<br>
<center>- 15 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(EE)  Meprobamate;<br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(DD)</strike>] <u><i>(FF)</i></u>  Methohexital;<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(FF)</strike>] <u><i>(GG)</i></u>  Methylphenobarbital (mephobarbital);<br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(GG)  Nemetazepam;</strike>]<br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(HH)  Midazolam;</i></u><br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(II)  Nimetazepam;</i></u><br>

7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(HH)</strike>] <u><i>(JJ)</i></u>  Nitrazepam;<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(II)</strike>] <u><i>(KK)</i></u>  Nordiazepam;<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(JJ)</strike>] <u><i>(LL)</i></u>  Oxazepam;<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(KK)</strike>] <u><i>(MM)</i></u>  Oxazolam;<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(LL)</strike>] <u><i>(NN)</i></u>  Paraldehyde;<br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(MM)  Penazepam;</strike>]<br>

13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(NN)</strike>] <u><i>(OO)</i></u>  Pentazocine;<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(OO)</strike>] <u><i>(PP)</i></u>  Petrichloral;<br>

15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(PP)</strike>] <u><i>(QQ)</i></u>  Phenobarbital;<br>

16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(RR)  Pinazepam;</i></u><br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(QQ)</strike>] <u><i>(SS)</i></u>  Prazepam;<br>

18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(RR)</strike>] <u><i>(TT)</i></u>  Quazepam;<br>

19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(SS)  Tempazepam;</strike>]<br>

20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(UU)  Temazepam;</i></u><br>

21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(TT)</strike>] <u><i>(VV)</i></u>  Tetrazepam; [<strike>and</strike>]<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(UU)  Treazolam.</strike>]<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(WW)  Triazolam; and</i></u><br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(XX)  Zolpidem.</i></u><br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  Any material, compound, mixture, or preparation of fenfluramine which contains any<br>

26&nbsp;&nbsp;&nbsp;&nbsp;quantity of the following substances, including its salts, isomers whether optical, position, or<br>

27&nbsp;&nbsp;&nbsp;&nbsp;geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers<br>

28&nbsp;&nbsp;&nbsp;&nbsp;is possible.<br>

29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  Unless specifically excepted or unless listed in another schedule, any material,<br>

30&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of the following substances having<br>

31&nbsp;&nbsp;&nbsp;&nbsp;a stimulant effect on the central nervous system, including its salts, isomers whether optical,<br>
<br>
<center>- 16 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers,<br>

2&nbsp;&nbsp;&nbsp;&nbsp;and salts of isomers is possible within the specific chemical designation:<br>

3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)  Cathine <u><i>((+)-norpseudoephedrine)</i></u>;<br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)  Diethylpropion;<br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)  Fencamfamine;<br>

6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)  Fenproprex;<br>

7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)  [<strike>Mazidole</strike>] <u><i>Mazindol</i></u>;<br>

8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(F)  Mefenorex;<br>

9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(H)</strike>] <u><i>(G)</i></u>  Pemoline, including organometallic complexes and chelates thereof;<br>

10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(G)</strike>] <u><i>(H)</i></u>  Phentermine;<br>

11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(I)  Pipradrol; and<br>

12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(J)SPA[<strike>((-)-1-climethylamino-1,2 diphenylethane)</strike>]<br>

13&nbsp;&nbsp;&nbsp;&nbsp;<u><i>((-)-1-dimethylamino-1,2-diphenylethane)</i></u>.<br>

14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  Unless specifically excepted or unless listed in another schedule, any material,<br>

15&nbsp;&nbsp;&nbsp;&nbsp;compound, mixture, or preparation which contains any quantity of dextropropoxyphene<br>

16&nbsp;&nbsp;&nbsp;&nbsp;(alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.<br>

17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)  Schedule V: Any compound, mixture, or preparation containing any of the following<br>

18&nbsp;&nbsp;&nbsp;&nbsp;limited quantities of narcotic drugs, or <u><i>their</i></u> salts [<strike>of any of them</strike>] <u><i>calculated as the free anhydrous</i></u><br>

19&nbsp;&nbsp;&nbsp;&nbsp;<u><i>base or alkaloid</i></u>, which includes one or more non-narcotic active medicinal ingredients in<br>

20&nbsp;&nbsp;&nbsp;&nbsp;sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal<br>

21&nbsp;&nbsp;&nbsp;&nbsp;qualities other than those possessed by the narcotic drug alone:<br>

22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;<br>

23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;<br>

24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)  not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;<br>

25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)  not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of<br>

26&nbsp;&nbsp;&nbsp;&nbsp;atropine sulfate per dosage unit;<br>

27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)  not more than 100 milligrams of opium per 100 milliliters or per 100 grams;<br>

28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)  not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine<br>

29&nbsp;&nbsp;&nbsp;&nbsp;sulfate per dosage unit; [<strike>and</strike>]<br>

30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)  unless specifically exempted or excluded or unless listed in another schedule, any<br>

31&nbsp;&nbsp;&nbsp;&nbsp;material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant effect<br>
<br>
<center>- 17 -</center>


<p><HR>

1&nbsp;&nbsp;&nbsp;&nbsp;on the central nervous system, including its salts, isomers, and salts of isomers[<strike>.</strike>]<u><i>; and</i></u><br>

2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>(viii)  unless specifically excepted or unless listed in another schedule, any material,</i></u><br>

3&nbsp;&nbsp;&nbsp;&nbsp;<u><i>compound, mixture, or preparation containing any Buprenorphine and its salts.</i></u><br>

4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 2.  <b> Informational note.</b><br>

5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>The symbols used in this bill do not appear in the electronic version.  Please refer to the</i></u><br>

6&nbsp;&nbsp;&nbsp;&nbsp;<u><i>hard copy version on file with the Utah House of Representatives or the Office of Legislative</i></u><br>

7&nbsp;&nbsp;&nbsp;&nbsp;<u><i>Printing to view these symbols.</i></u><br>
<br>
<br>
<br>
<br>

<!-- End of font TimesNewRomanRegular with size 12 --><font size=+1><b> Legislative Review Note<br>
&nbsp;&nbsp;&nbsp;&nbsp;as of   1-23-98  12:13 PM</b></font>
<!-- Font changed to TimesNewRomanRegular with size 12 --><br>
<br>
A limited legal review of this bill raises no obvious constitutional or statutory concerns.<br>
<br>
<Div align="right"><b> Office of Legislative Research and General Counsel</b></Div>
<br>
<br>
<center>- 18 -<p>


<HR><a href="/~1998/htmdoc/hbillhtm/HB0309.htm">[Bill Documents]</a><a href="/~1998/bills.htm">[Bills Directory]</a>
<p>

	
    </div><!-- /#content -->
	
  </div><!-- /#main -->
<div class="clear"></div><!-- /.clear -->
</div><!-- /#wrapper -->

  <footer>
  	<div id="myreps" class="left three" style="display:none">
    </div>
	<form id="whorep" class="three left" method="post" action="/GIS/findDistrict.jsp">
		<h4>Who represents me?</h4>
		<p>
			<input type="text" id="faddress" name="address" placeholder="Enter Street address" title="Enter street address" />
		</p>
		
		<p>
			<input type="text" id="fzip" name="zip" title="Enter zip code" placeholder="Enter zip code" /><br> 	
			
           <div style="float:left; width:100%"><input type="checkbox" name="rememberReps" id="rememberReps" /><label id="rememberRepslbl" for="rememberReps">Remember my Legislators</label></div>
           <input type="submit" value="Map it" />
		</p>
	</form><!-- /#representative -->
	
	
	<div class="three left">
		<div class="info left" id="senate">
        <a href="http://senate.utah.gov/"><img src="/images/seal-senate.png" alt="Utah Senate"></a>
		<h5>State Senate</h5>
		350 North State, Suite 320<br/>
		PO Box 145115<br/>
		Salt Lake City, Utah 84114<br/>

		Telephone: (801) 538-1035<br/>
		Fax: (801) 326-1475<br/>
		</div><!-- /#senate .info -->
	
		<div class="info right" id="represenatives">
        <a href="https://house.utah.gov/"><img src="/images/seal-represenatives.png" alt="Utah House of Representatives"></a>
		<h5>House of Representatives</h5>
		350 North State, Suite 350<br/>
		PO Box 145030<br/>
		Salt Lake City, Utah 84114<br/>

		Telephone: (801) 538-1029<br/>
		Fax: (801) 326-1544<br/>
		</div><!-- /#representatives .info -->	
	</div><!-- /.three -->
	
	<form id="feedback" name="feedback" class="three right">
    	
		<textarea name="comments" id="comments" placeholder="How can we improve this page?   For a personal response, please include your email address." title="How can we improve this site?   For a personal response, please include your email address." ></textarea>
        <!--<input name="feedemail" id="feedemail" class="feedemail" type="text" placeholder="Enter email address for a response" style="display:none;">
		<input id="feedbtn2" type="submit" style="display:none;" value="No Thanks"/>-->
        <input id="feedbtn" type="submit" value="Send"/>
        <span id="getemailtext" style="display:none;"></span>
        <input id="bdata" type="hidden" name="bdata" value="" />
        
	</form><!-- /#feedback -->
	
	<ul id="footcrumb">
		<li><a href="/">Home</a></li>
		<li><a href="/mobile.asp">Mobile Site</a></li>
        	<li><a href="/sitemap.htm">Site Map</a></li>
		<li><a href="/asp/interim/Cal.asp">Calendar</a></li>
		<li><a href="/xcode/code.html">Code / Constitution</a></li>
		<li><a href="https://house.utah.gov/">House</a></li>
		<li><a href="http://senate.utah.gov/">Senate</a></li>
		<!--<li><a href="/documents/comments.htm">Questions/Comments</a></li>-->
		<li><a href="/documents/disclaimer.htm">Terms of Use/Privacy Policy</a></li>
        <!--<li><a onclick="applyPrintStyle()">Print Friendly Version</a></li>-->
        <li><a href="/documents/ADAnotice.htm" class="mlink">ADA</a></li>
        <li><a href="http://utah.gov" class="mlink">Utah.gov</a></li>
	</ul><!-- /#footcrumb -->
	<div class="clear"></div>
  </footer>

  <!-- Google CDN's jQuery, with a protocol relative URL; fall back to local if offline 
  <script src="//ajax.googleapis.com/ajax/libs/jquery/1.7.1/jquery.min.js"></script>
  <script>window.jQuery || document.write('<script src="/js/libs/jquery-1.7.1.min.js"><\/script>')</script>-->

  <!-- Scripts -->
  
  <script src="/js/functions.js"></script>
	
  <!-- Asynchronous Google Analytics 
  <script>
  	var _gaq=[['_setAccount','UA-15325774-34'],['_trackPageview']];
    (function(d,t){var g=d.createElement(t),s=d.getElementsByTagName(t)[0];
    g.src=('https:'==location.protocol?'//ssl':'//www')+'.google-analytics.com/ga.js';
    s.parentNode.insertBefore(g,s)}(document,'script'));
  </script>-->
</body>
</html>

